Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Advances in understanding the regulatory functions of the nervous system have revealed
neural cholinergic signaling as a key regulator of cytokine responses and inflammation …

Cognitive impairments associated with schizophrenia (CIAS) represent a central element of
the symptomatology of this severe mental disorder. CIAS substantially determine the …

Cancer chemotherapy-induced cognitive impairment (chemobrain) is a major complication
that affects the prognosis of therapy. Our study evaluates the nootropic-like activity of …

Background: Schizophrenia is a severe and enduring disease and is one of the leading
causes of disability worldwide. Cognitive impairment is a core clinical symptom that plays a …

Recent evidence supports accelerated cognitive decline and brain changes in middle-aged
and older people with schizophrenia, relative to the general population. More research in …

Cancer chemotherapy is known to cause cognitive defects in patients. Our study
investigated the effect of piracetam (PIRA; 200 or 400 mg/kg) against doxorubicin (DOX) …

Acetylcholinesterase (AChE) is an important drug target in neurological disorders like
Alzheimer's disease, Lewy body dementia, and Parkinson's disease dementia as well as for …

Acetylcholine (ACh) signaling is critical for central nervous function and is known to be
abnormal in schizophrenia (SZ), a chronic neuropsychiatric disorder in which cognitive …